Foresee Pharmaceuticals Co., Ltd.
Research Foresee Pharmaceuticals Co., Ltd. (6576.TWO) on Bullrun: market cap TWD 12.23B, P/E 554.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6576.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 12.23B
- P/E554.3
- Financial periodQ2 2026
- RevenueTWD 181.65M
- Net income-TWD 123.78M
- Free cash flowTWD 24.97M
- Gross margin76.2%
Valuation Snapshot
latest market cap is TWD 12.23B; P/E is 554.3.
Peer valuation comparison
Latest P/E is 554.29x versus a Healthcare sector median of 21.8x (2443.2% above).
Latest P/E is 554.29x versus a Taiwan median of 18.67x (2869.1% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 12.23B | 554.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Foresee Pharmaceuticals Co., Ltd.
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases.
ETFs that hold Foresee Pharmaceuticals Co., Ltd.
US-listed ETFs
Foresee Pharmaceuticals Co., Ltd. is held by 6 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.03% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Foresee Pharmaceuticals Co., Ltd.'s market cap?
Foresee Pharmaceuticals Co., Ltd.'s market capitalization is TWD 12.23B.
What is Foresee Pharmaceuticals Co., Ltd.'s P/E ratio?
Foresee Pharmaceuticals Co., Ltd.'s price-to-earnings (P/E) ratio is 554.3.
What does Foresee Pharmaceuticals Co., Ltd. do?
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases.